Chromatin modifying agents - The cutting edge of anticancer therapy

Faith A. A. Kwa, Aneta Balcerczyk, Paul Licciardi, Assam El-Osta, Tom C. Karagiannis

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Chromatin modifying compounds are emerging as the next generation of anticancer therapies. By altering gene expression they could be able to correct uncontrolled proliferation and, in certain cases, aberrant apoptotic pathways, which are hallmarks of malignant cells. The modulation of gene expression is regulated via chromatin remodelling processes that include DNA methylation and chromatin modifications. The identification of aberrant methylation of genes and dysregulated histone acetylation status in cancer cells provides a basis for novel epigenetic therapies. Currently available chromatin modifying agents, a group that includes DNA methyltransferase and histone deacetylase inhibitors, exert anticancer effects by reactivating tumour suppressor genes, inhibiting proliferation and inducing apoptosis. It is anticipated that massive parallel sequencing will identify new epigenetic targets for drug development.

Original languageEnglish
Pages (from-to)543-547
Number of pages5
JournalDrug Discovery Today
Volume16
Issue number13-14
DOIs
Publication statusPublished - Jul 2011
Externally publishedYes

Cite this

Kwa, Faith A. A. ; Balcerczyk, Aneta ; Licciardi, Paul ; El-Osta, Assam ; Karagiannis, Tom C. / Chromatin modifying agents - The cutting edge of anticancer therapy. In: Drug Discovery Today. 2011 ; Vol. 16, No. 13-14. pp. 543-547.
@article{67313b6b52cf495fbdf7a5dfc0c34e0d,
title = "Chromatin modifying agents - The cutting edge of anticancer therapy",
abstract = "Chromatin modifying compounds are emerging as the next generation of anticancer therapies. By altering gene expression they could be able to correct uncontrolled proliferation and, in certain cases, aberrant apoptotic pathways, which are hallmarks of malignant cells. The modulation of gene expression is regulated via chromatin remodelling processes that include DNA methylation and chromatin modifications. The identification of aberrant methylation of genes and dysregulated histone acetylation status in cancer cells provides a basis for novel epigenetic therapies. Currently available chromatin modifying agents, a group that includes DNA methyltransferase and histone deacetylase inhibitors, exert anticancer effects by reactivating tumour suppressor genes, inhibiting proliferation and inducing apoptosis. It is anticipated that massive parallel sequencing will identify new epigenetic targets for drug development.",
author = "Kwa, {Faith A. A.} and Aneta Balcerczyk and Paul Licciardi and Assam El-Osta and Karagiannis, {Tom C.}",
year = "2011",
month = "7",
doi = "10.1016/j.drudis.2011.05.012",
language = "English",
volume = "16",
pages = "543--547",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "13-14",

}

Chromatin modifying agents - The cutting edge of anticancer therapy. / Kwa, Faith A. A.; Balcerczyk, Aneta; Licciardi, Paul ; El-Osta, Assam; Karagiannis, Tom C.

In: Drug Discovery Today, Vol. 16, No. 13-14, 07.2011, p. 543-547.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Chromatin modifying agents - The cutting edge of anticancer therapy

AU - Kwa, Faith A. A.

AU - Balcerczyk, Aneta

AU - Licciardi, Paul

AU - El-Osta, Assam

AU - Karagiannis, Tom C.

PY - 2011/7

Y1 - 2011/7

N2 - Chromatin modifying compounds are emerging as the next generation of anticancer therapies. By altering gene expression they could be able to correct uncontrolled proliferation and, in certain cases, aberrant apoptotic pathways, which are hallmarks of malignant cells. The modulation of gene expression is regulated via chromatin remodelling processes that include DNA methylation and chromatin modifications. The identification of aberrant methylation of genes and dysregulated histone acetylation status in cancer cells provides a basis for novel epigenetic therapies. Currently available chromatin modifying agents, a group that includes DNA methyltransferase and histone deacetylase inhibitors, exert anticancer effects by reactivating tumour suppressor genes, inhibiting proliferation and inducing apoptosis. It is anticipated that massive parallel sequencing will identify new epigenetic targets for drug development.

AB - Chromatin modifying compounds are emerging as the next generation of anticancer therapies. By altering gene expression they could be able to correct uncontrolled proliferation and, in certain cases, aberrant apoptotic pathways, which are hallmarks of malignant cells. The modulation of gene expression is regulated via chromatin remodelling processes that include DNA methylation and chromatin modifications. The identification of aberrant methylation of genes and dysregulated histone acetylation status in cancer cells provides a basis for novel epigenetic therapies. Currently available chromatin modifying agents, a group that includes DNA methyltransferase and histone deacetylase inhibitors, exert anticancer effects by reactivating tumour suppressor genes, inhibiting proliferation and inducing apoptosis. It is anticipated that massive parallel sequencing will identify new epigenetic targets for drug development.

UR - http://www.scopus.com/inward/record.url?scp=79959765942&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2011.05.012

DO - 10.1016/j.drudis.2011.05.012

M3 - Review Article

VL - 16

SP - 543

EP - 547

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 13-14

ER -